Aprogen Biologics Inc. (KRX:003060)
South Korea
· Delayed Price · Currency is KRW 715.00
-5.00 (-0.69%)
Last updated: Apr 18, 2025
Aprogen Biologics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Other Revenue | - | - | - | - | 0 | Upgrade
|
| Revenue | 67,378 | 87,364 | 65,190 | 56,482 | 53,320 | Upgrade
|
| Revenue Growth (YoY) | -22.88% | 34.01% | 15.42% | 5.93% | 4.75% | Upgrade
|
| Cost of Revenue | 75,224 | 99,337 | 39,380 | 31,607 | 30,515 | Upgrade
|
| Gross Profit | -7,846 | -11,974 | 25,810 | 24,875 | 22,805 | Upgrade
|
| Selling, General & Admin | 26,343 | 29,789 | 28,914 | 25,947 | 23,579 | Upgrade
|
| Research & Development | 18,035 | 15,000 | 2,187 | 1,735 | 697.7 | Upgrade
|
| Other Operating Expenses | 383.38 | 357.6 | 365.27 | 416.95 | 592.21 | Upgrade
|
| Operating Expenses | 50,730 | 58,716 | 30,015 | 28,850 | 23,885 | Upgrade
|
| Operating Income | -58,577 | -70,690 | -4,204 | -3,975 | -1,081 | Upgrade
|
| Interest Expense | -5,514 | -3,668 | -274.41 | -31.14 | -49.06 | Upgrade
|
| Interest & Investment Income | 4,242 | 4,488 | 16,645 | 13,587 | 9,176 | Upgrade
|
| Earnings From Equity Investments | 19,018 | 79,786 | 94.73 | 352.2 | 1,510 | Upgrade
|
| Currency Exchange Gain (Loss) | -20.53 | -6.22 | 33.16 | 12.72 | -26.11 | Upgrade
|
| Other Non Operating Income (Expenses) | -10,015 | 564.26 | 209.78 | 347.85 | 423.69 | Upgrade
|
| EBT Excluding Unusual Items | -50,865 | 10,474 | 12,504 | 10,294 | 9,953 | Upgrade
|
| Gain (Loss) on Sale of Investments | -57,999 | 29,950 | 2,638 | 1,623 | 6,341 | Upgrade
|
| Gain (Loss) on Sale of Assets | 16.15 | -151,537 | 3.1 | 53.08 | 593.48 | Upgrade
|
| Asset Writedown | -154.08 | -2,271 | -264.15 | -2,134 | -241.5 | Upgrade
|
| Other Unusual Items | 4,023 | - | -1.04 | -4.76 | -2.67 | Upgrade
|
| Pretax Income | -104,980 | -113,383 | 14,881 | 9,831 | 16,644 | Upgrade
|
| Income Tax Expense | - | 1,947 | 1,260 | 679.69 | -2,274 | Upgrade
|
| Earnings From Continuing Operations | -104,980 | -115,330 | 13,621 | 9,151 | 18,918 | Upgrade
|
| Minority Interest in Earnings | 0.72 | -2,940 | -981.32 | -1,048 | -7,665 | Upgrade
|
| Net Income | -104,979 | -118,270 | 12,639 | 8,103 | 11,253 | Upgrade
|
| Net Income to Common | -104,979 | -118,270 | 12,639 | 8,103 | 11,253 | Upgrade
|
| Net Income Growth | - | - | 55.99% | -27.99% | - | Upgrade
|
| Shares Outstanding (Basic) | 126 | 63 | 40 | 40 | 32 | Upgrade
|
| Shares Outstanding (Diluted) | 126 | 63 | 40 | 40 | 32 | Upgrade
|
| Shares Change (YoY) | 99.40% | 56.07% | 1.42% | 25.52% | 94.17% | Upgrade
|
| EPS (Basic) | -834.56 | -1874.81 | 312.69 | 203.29 | 354.38 | Upgrade
|
| EPS (Diluted) | -835.00 | -1875.00 | 310.00 | 200.00 | 350.00 | Upgrade
|
| EPS Growth | - | - | 55.00% | -42.86% | - | Upgrade
|
| Free Cash Flow | -46,261 | -61,739 | 24,444 | -7,023 | 7,112 | Upgrade
|
| Free Cash Flow Per Share | -367.76 | -978.68 | 604.74 | -176.20 | 223.97 | Upgrade
|
| Gross Margin | -11.64% | -13.71% | 39.59% | 44.04% | 42.77% | Upgrade
|
| Operating Margin | -86.94% | -80.92% | -6.45% | -7.04% | -2.03% | Upgrade
|
| Profit Margin | -155.81% | -135.38% | 19.39% | 14.34% | 21.10% | Upgrade
|
| Free Cash Flow Margin | -68.66% | -70.67% | 37.50% | -12.43% | 13.34% | Upgrade
|
| EBITDA | -39,486 | -49,292 | -1,800 | -1,903 | 851.33 | Upgrade
|
| EBITDA Margin | -58.60% | -56.42% | -2.76% | -3.37% | 1.60% | Upgrade
|
| D&A For EBITDA | 19,090 | 21,398 | 2,404 | 2,072 | 1,932 | Upgrade
|
| EBIT | -58,577 | -70,690 | -4,204 | -3,975 | -1,081 | Upgrade
|
| EBIT Margin | -86.94% | -80.92% | -6.45% | -7.04% | -2.03% | Upgrade
|
| Effective Tax Rate | - | - | 8.47% | 6.91% | - | Upgrade
|
| Advertising Expenses | 521.48 | 736.69 | 1,371 | 7,800 | 4,343 | Upgrade
|
Updated Mar 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.